US-listed shares of NewAmsterdam Pharma fall on planned $300 mln public offering

NewAmsterdam Pharma

11/12/2024 17:05

** U.S-listed shares of drug developer NewAmsterdam Pharma
 NAMS.O  fall as much as 5.8%; last down 4.7% at $24.95
    ** NAMS late Tuesday announced commencement of a $300 mln
public offering of shares and pre-funded warrants
    ** Offering commenced after NAMS terminated up to $150 mln
"at-the-market" stock sale agreement with TD Cowen
    ** Jefferies, Goldman Sachs, Leerink Partners, TD Cowen,
Guggenheim Securities and William Blair are the joint
book-running managers for the offering
    ** Stock also rose 41.4% on Tuesday after NAMS reported data
from a late-stage study that showed its experimental drug
significantly reduced levels of low-density lipoprotein
cholesterol
    ** NAMS has 92.4 mln outstanding shares and a $2.42 bln
market capitalization as of last close - LSEG data
    ** As of last close, NAMS shares had more than doubled YTD


 (Reporting by Arasu Kannagi Basil in Bengaluru)
 ((ArasuKannagi.Basil@thomsonreuters.com;))